Publications by authors named "Richard D Kim"

Claim this Profile
A
A phase II study of trifluridine/tipiracil in combination with ramucirumab in advanced, refractory gastric, or gastroesophageal junction adenocarcinomas.
Dae Won Kim, Richard D Kim, Maria Martinez Jimenez, Youngchul Kim, Rutika Mehta

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Anthony B El-Khoueiry, Richard D Kim, William P Harris, Max W Sung, Dirk Waldschmidt

Hepatology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrahepatic cholangiocarcinoma: role of imaging as a critical component for multi-disciplinary treatment approach.
Betzaira G Childers, Jason W Denbo, Richard D Kim, Sarah E Hoffe, Tetiana Glushko

Abdom Radiol (NY)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of neoadjuvant therapies in locally advanced colon cancer.
Tiago Biachi de Castria, Gabriel Lenz, Gabriel Valagni, Richard D Kim

Chin Med J (Engl)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Study of Patients with Metastatic Colorectal Cancer and Long-Term Response to Regorafenib in the USA.
Richard D Kim, Xiaoyun Pan, Yiqiao Zhang, Orsolya Lunacsek, Federica Pisa

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy.
James Yu, Jose M Laborde, Robin Park, Moazzam Shahzad, Youngchul Kim, Richard D Kim, Dae Won Kim

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study.
Maen Abdelrahim, Abdullah Esmail, Richard D Kim, Sukeshi Patel Arora, Junaid Arshad

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer.
Ruoyu Miao, James Yu, Richard D Kim

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of current treatments for advanced cholangiocarcinoma.
Tiago Biachi de Castria, Richard D Kim

Expert Opin Drug Saf· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer.
Shahla Bari, Marco Matejcic, Richard D Kim, Hao Xie, Ibrahim H Sahin

JAMA Netw Open· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection.
James Yu, Aiwu Ruth He, Mahmoud Ouf, Rutika Mehta, Daniel A Anaya, Richard D Kim

JCO Precis Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter].
Tiago Biachi de Castria, Richard D Kim

Pragmat Obs Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Standards of Care in the Management of Localized Colorectal Cancer.
Benjamin A Weinberg, Paul E Sackstein, James Yu, Richard D Kim, Joshua Sommovilla

Am Soc Clin Oncol Educ Book· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights.
Tiago Biachi de Castria, Richard D Kim

Pragmat Obs Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the treatment of anal cancer: an overview of the latest investigational drugs.
James Yu, Richard D Kim

Expert Opin Investig Drugs· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report.
James Yu, Trenton A Avriett, Christopher M Ray, Richard D Kim

J Gastrointest Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.
Dae Won Kim, Young-Chul Kim, Bence P Kovari, Maria Martinez, Ruoyu Miao, Richard D Kim

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
Bela Kis, Ravi Shridhar, Rahul Mhaskar, Marcell Gyano, Jessica M Frakes, Richard D Kim

J Vasc Interv Radiol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Lingbin Meng, Ram Thapa, Maria G Delgado, Maria F Gomez, Rui Ji, Richard D Kim

JAMA Netw Open· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer.
Junjia Liu, Xuefeng Wang, Ibrahim H Sahin, Iman Imanirad, Seth I Felder, Richard D Kim

Am J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in Biliary Tract Cancers: Where Are We?
Aparna Kalyan, Harshit Khosla, Richard D Kim

Curr Oncol Rep· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer.
Dae Won Kim, Young-Chul Kim, Bence P Kovari, Vincent Chung, Olatunji B Alese, Richard D Kim

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
Richard D Kim, Bence P Kovari, Maria Martinez, Hao Xie, Ibrahim H Sahin, Young-Chul Kim, Dae Won Kim

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter?
Andrew J Sinnamon, Anthony C Wood, Megan A Satyadi, Catherine V Levitt, Olivia Hardy, Richard D Kim

J Gastrointest Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
Hao Xie, Diego M Alem Glison, Richard D Kim

Expert Opin Investig Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis